Tevogen Bio Holdings Inc. (TVGN) is considering a special cash dividend to shareholders based on future financial milestones, pending board approval. The company focuses on affordable healthcare solutions using AI and precision T cell therapy. Tevogen Bio has completed a successful clinical trial, with a pipeline in virology, oncology, and neurology. Tevogen.AI aims to accelerate drug development by predicting protein combinations, while future initiatives may include generics, biosimilars, and medical devices. Forward-looking statements caution potential risks and uncertainties. Further updates will follow as necessary.

Read more at GlobeNewswire: Tevogen Board to Evaluate Potential One-Time Special Cash